MilliporeSigma
  • Home
  • Search Results
  • Effects of an anti-inflammatory VAP-1/SSAO inhibitor, PXS-4728A, on pulmonary neutrophil migration.

Effects of an anti-inflammatory VAP-1/SSAO inhibitor, PXS-4728A, on pulmonary neutrophil migration.

Respiratory research (2015-04-19)
Heidi C Schilter, Adam Collison, Remo C Russo, Jonathan S Foot, Tin T Yow, Angelica T Vieira, Livia D Tavares, Joerg Mattes, Mauro M Teixeira, Wolfgang Jarolimek
ABSTRACT

The persistent influx of neutrophils into the lung and subsequent tissue damage are characteristics of COPD, cystic fibrosis and acute lung inflammation. VAP-1/SSAO is an endothelial bound adhesion molecule with amine oxidase activity that is reported to be involved in neutrophil egress from the microvasculature during inflammation. This study explored the role of VAP-1/SSAO in neutrophilic lung mediated diseases and examined the therapeutic potential of the selective inhibitor PXS-4728A. Mice treated with PXS-4728A underwent intra-vital microscopy visualization of the cremaster muscle upon CXCL1/KC stimulation. LPS inflammation, Klebsiella pneumoniae infection, cecal ligation and puncture as well as rhinovirus exacerbated asthma models were also assessed using PXS-4728A. Selective VAP-1/SSAO inhibition by PXS-4728A diminished leukocyte rolling and adherence induced by CXCL1/KC. Inhibition of VAP-1/SSAO also dampened the migration of neutrophils to the lungs in response to LPS, Klebsiella pneumoniae lung infection and CLP induced sepsis; whilst still allowing for normal neutrophil defense function, resulting in increased survival. The functional effects of this inhibition were demonstrated in the RV exacerbated asthma model, with a reduction in cellular infiltrate correlating with a reduction in airways hyperractivity. This study demonstrates that the endothelial cell ligand VAP-1/SSAO contributes to the migration of neutrophils during acute lung inflammation, pulmonary infection and airway hyperractivity. These results highlight the potential of inhibiting of VAP-1/SSAO enzymatic function, by PXS-4728A, as a novel therapeutic approach in lung diseases that are characterized by neutrophilic pattern of inflammation.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Sodium phosphate, 96%
Sigma-Aldrich
Urea, puriss., meets analytical specification of Ph. Eur., BP, USP, 99.0-100.5%, 99.0-101.0% (calc. on dry substance)
Sigma-Aldrich
Urea, puriss. p.a., ACS reagent, reag. Ph. Eur., ≥99%
Sigma-Aldrich
Urea, BioUltra, for molecular biology, ≥99% (T)
Sigma-Aldrich
Urea, ACS reagent, 99.0-100.5%
Sigma-Aldrich
Urea, ReagentPlus®, ≥99.5%, pellets
Sigma-Aldrich
Urea, suitable for electrophoresis
Sigma-Aldrich
Urea, BioXtra, pH 7.5-9.5 (20 °C, 5 M in H2O)
Sigma-Aldrich
Urea, meets USP testing specifications
Sigma-Aldrich
Urea, powder, BioReagent, for molecular biology, suitable for cell culture
Sigma-Aldrich
Tyramine, 98%, FG
Sigma-Aldrich
Tyramine, ≥98.0%
Urea, European Pharmacopoeia (EP) Reference Standard
Supelco
Tyramine, analytical standard
Supelco
Urea, analytical standard
Supelco
Urea, 8 M (after reconstitution with 16 mL high purity water)
USP
Urea, United States Pharmacopeia (USP) Reference Standard
Supelco
4-Aminobenzoic acid, analytical standard
Sigma-Aldrich
Phenylmethanesulfonyl fluoride, ≥98.5% (GC)
Sigma-Aldrich
4-Aminobenzoic acid, purified by sublimation, ≥99%
Sigma-Aldrich
1,4-Diaminobutane, 99%
Sigma-Aldrich
Urea-12C, 99.9 atom % 12C
Sigma-Aldrich
Urea solution, BioUltra, ~8 M in H2O
Sigma-Aldrich
Phenylmethanesulfonyl fluoride, ≥99.0% (T)
Sigma-Aldrich
4-Aminobenzoic acid, ReagentPlus®, 99%
Sigma-Aldrich
Urea solution, 40 % (w/v) in H2O
Sigma-Aldrich
4-Aminobenzoic acid, ReagentPlus®, ≥99%
Millipore
Urea solution, suitable for microbiology, 40% in H2O
4-Aminobenzoic acid, European Pharmacopoeia (EP) Reference Standard
Supelco
Putrescine, analytical standard